Table 3.
Histopathological and immunohistochemical changes in individual tumor samples induced by eCPMV immunotherapy
| Patient | Ki-67 (%) | CC-3 (%) | MPO (%) | IL-8 | CD3* | CD20* | FoxP3* | FoxP3/CD3 | Total necrosis (%)‡ | NAN (%) | nNAN (%) |
| eCPMV-treated canine IMC patients | |||||||||||
| P1 | |||||||||||
| Pretreated | † | † | 0.86 | 0.00 | 241.89 | 162.53 | 63.68 | 0.26 | 0.00 | 0.00 | 0.00 |
| Post-treated (day 92) | 41.42 | 12.00 | 15.45 | 2.00 | 1422.32 | 944.63 | 133.05 | 0.09 | 5.38 | 5.19 | 0.19 |
| P2 | |||||||||||
| Pretreated | 37.93 | 17.09 | 0.99 | 0.00 | 258.21 | 318.63 | 107.25 | 0.42 | 0.63 | 0.00 | 0.63 |
| Post-treated (day 156) | 29.48 | 5.18 | 2.09 | 2.00 | 343.89 | 80.42 | 77.51 | 0.23 | 0.97 | 0.47 | 0.50 |
| P5 | |||||||||||
| Pretreated | 60.75 | 1.00 | 1.14 | 0.00 | 253.79 | 130.32 | 99.73 | 0.39 | 0.59 | 0.00 | 0.59 |
| Post-treated (day 17) | 38.59 | 6.41 | 9.62 | 2.00 | 759.79 | 162.74 | 88.15 | 0.12 | 2.21 | 1.43 | 0.78 |
| Control canine IMC patients | |||||||||||
| P6 | 82.24 | 8.36 | 0.56 | 0.00 | 107.16 | 160.32 | 41.47 | 0.39 | 0.04 | 0.04 | 0.00 |
| P7 | 70.70 | 3.29 | 2.50 | 0.00 | 258.21 | 145.58 | 57.88 | 0.22 | 0.01 | 0.00 | 0.01 |
| P8 | 48.88 | 3.13 | 0.26 | 1.00 | 326.00 | 307.26 | 142.74 | 0.44 | 0.00 | 0.00 | 0.00 |
*The number of CD3-positive, CD20-positive, and FoxP3-positive cells is provided per mm2.
†Ki-67 and CC-3 percentages were not calculated for pretreatment biopsy of P1 due to the low availability of neoplastic cells in the pretreatment biopsy.
‡The presence of necrosis (total, neutrophil and non-neutrophil associated) was the only histopathological change assessed in H&E.
CC-3, cleaved caspase-3; eCPMV, empty cowpea mosaic virus; IL-8, interleukin-8; IMC, inflammatory mammary cancer; MPO, myeloperoxidase; NAN, neutrophil-associated necrosis; nNAN, non-neutrophil-associated necrosis.